Researchers at the University of California, Berkeley, have identified an oral compound named TOFA that significantly reduces body weight in obese mice by boosting energy expenditure rather than suppressing appetite. This study highlights the potential for TOFA to preserve muscl…
This article examines the potential of GLP-1 receptor agonists, commonly used for type 2 diabetes and obesity, in treating polyendocrine metabolic ovarian syndrome (PMOS). Experts…
A study published in Science Advances reveals that the experimental drug TOFA enables obese mice to lose fat without reducing their food intake or losing muscle mass. The compound…
As obesity medications evolve, researchers are exploring new hormone combinations to enhance treatment effectiveness and tolerability. Current studies focus on therapies that not…
The death of 19-year-old Josephine Nasr, a law student in London, has sparked serious concerns regarding the safety of tirzepatide, a GLP-1 weight loss drug. Following her prescri…
The Health Products Regulatory Authority (HPRA) has confirmed over 1,500 reports of suspected adverse reactions related to anti-obesity medications, including serious gastrointest…
A recent study published in The BMJ indicates that tirzepatide, a GLP-1 medication, may lower the risk of major cardiovascular events by 33% in patients with type 2 diabetes and h…
A recent study published in Diabetes, Obesity and Metabolism indicates that GLP-1 drugs, commonly used to treat type 2 diabetes and obesity, may also lower the risk of age-related…
GLP-1 receptor agonists are primarily known for aiding weight loss, but emerging research indicates they may also provide significant cardiovascular and renal benefits. This artic…
The Medicines and Healthcare products Regulatory Agency (MHRA) emphasizes the importance of safe practices in weight loss, particularly regarding GLP-1 medications. As demand for…
As GLP-1 medications like Wegovy and Mounjaro gain popularity for weight loss, concerns arise about the potential for yo-yo dieting once treatment stops. Evidence suggests that ma…
A recent analysis reveals that while obesity drugs like GLP-1s can lead to significant weight loss, they often do not enhance quality of life or cardiovascular health for many pat…
Apnimed is preparing for a $160 million initial public offering on the Nasdaq to support the development of its lead therapy for obstructive sleep apnoea (OSA). The Massachusetts-…
As international drug companies ramp up their demands for higher prices, Australia faces a looming crisis in access to essential medications, leading to a farcical standoff that p…